Vanguard Capital Management’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$113M Buy
4,608,292
+8,855
+0.2% +$246K ﹤0.01% 1459
2026
Q2
$158M Buy
4,599,437
+222,063
+5% +$6.7M ﹤0.01% 1294
2026
Q1
$104M Buy
+4,377,374
New +$121M ﹤0.01% 1447

Other funds holding BEAM

Vanguard Capital Management's BEAM Position: Q3 2026 in Review

Vanguard Capital Management increased its Beam Therapeutics (BEAM) stake by 0.19% in Q3 2026, buying an estimated $246K and bringing the position to 4,608,292 shares worth $113M. The position accounts for ﹤0.01% of the portfolio, ranked #1459.

Vanguard Capital Management first reported a position in BEAM in Q1 2026 and has held it in 3 quarters since. The position peaked at $158M in Q2 2026. 262 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.

  • Vanguard Capital Management held 4,608,292 shares of Beam Therapeutics worth $113M as of Q3 2026.
  • Vanguard Capital Management bought 8,855 Beam Therapeutics shares in Q3 2026, an estimated $246K.
  • Beam Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1459 holding.
  • Vanguard Capital Management first reported a position in Beam Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Beam Therapeutics position peaked at $158M in Q2 2026.
  • 262 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.